View Older Stories View More Recent Stories

Sep 8, 2020 08:05AM Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results
Sep 3, 2020 04:13PM Savara (SVRA) to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With CF
Sep 3, 2020 04:05PM Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)
Aug 6, 2020 04:02PM Savara Reports Second Quarter 2020 Financial Results and Provides Business Update
Aug 5, 2020 08:05AM Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually
Jul 30, 2020 08:05AM Savara to Report Second Quarter 2020 Financial Results and Provide Business Update
May 27, 2020 04:05PM  Savara to Present at the Jefferies Virtual Healthcare Conference
May 8, 2020 08:05AM Savara Announces Change of Date for 2020 Annual Meeting of Stockholders
May 7, 2020 04:05PM Savara Reports First Quarter 2020 Financial Results and Provides Business Update
Apr 30, 2020 04:05PM Savara to Report First Quarter 2020 Financial Results and Provide Business Update
Apr 2, 2020 04:05PM Savara Obtains Global Rights to Develop and Commercialize Apulmiq
Mar 30, 2020 04:11PM Savara (SVRA) announces enrollment has been terminated in Phase 3 AVAIL and Phase 2a ENCORE studies
Mar 30, 2020 04:05PM Savara Provides Business Update in Response to COVID-19 Pandemic
Mar 12, 2020 04:05PM Savara Reports Fourth Quarter / Year-End 2019 Financial Results and Provides Business Update
Mar 5, 2020 08:05AM Savara to Report Fourth Quarter/Year-End 2019 Financial Results and Provide Business Update
Dec 30, 2019 08:05AM Savara (SVRA) Granted Breakthrough Therapy Designation for Molgradex for Treatment of aPAP
Dec 30, 2019 08:05AM Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Dec 3, 2019 04:12PM Savara (SVRA) Names Dr. An van Es-Johansson to Board
Dec 3, 2019 04:05PM Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors
Nov 27, 2019 04:05PM Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Nov 26, 2019 04:05PM Savara’s COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Nov 18, 2019 08:05AM Savara Appoints Badrul Chowdhury, M.D., Ph.D as Chief Medical Officer
Nov 12, 2019 04:05PM Savara to Present at the Stifel 2019 Healthcare Conference
Nov 7, 2019 04:05PM Savara Reports Third Quarter 2019 Financial Results and Provides Business Update
Oct 31, 2019 04:05PM Savara to Report Third Quarter 2019 Financial Results and Provide Business Update
Oct 2, 2019 08:08AM Savara (SVRA) Announces FDA Response From Type C Meeting on Molgradex for aPAP Development, FDA Did Not Recommend that it Submit BLA
Oct 2, 2019 08:02AM Savara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development Program
Sep 18, 2019 04:15PM Savara to Present Comprehensive Data From Pivotal Phase 3 IMPALA Study at 2019 ERS
Aug 8, 2019 04:02PM Savara Reports Second Quarter 2019 Financial Results and Provides Business Update
Aug 1, 2019 08:02AM Savara to Report Second Quarter 2019 Financial Results and Provide Business Update
Jul 31, 2019 08:02AM Savara to Present at the 39th Annual Canaccord Genuity Global Growth Conference
Jun 13, 2019 04:02PM Savara to Present at the JMP Securities Life Sciences Conference
Jun 12, 2019 04:04PM Savara (SVRA) Phase 3 Study of Molgradex for Treatment of aPAP Did not Meet its Primary Endpoint
Jun 12, 2019 04:02PM Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)
May 9, 2019 04:02PM Savara Reports First Quarter 2019 Financial Results and Provides Business Update
May 6, 2019 08:11AM Savara (SVRA) Announces Molgradex Received Fast Track Designation by FDA for Treatment of Autoimmune Pulmonary Alveolar Proteinosis
May 6, 2019 08:02AM Savara Announces Molgradex Received Fast Track Designation by FDA for Treatment of Autoimmune Pulmonary Alveolar Proteinosis
May 2, 2019 08:02AM Savara to Report First Quarter 2019 Financial Results and Provide Business Update
Apr 2, 2019 08:00AM Savara to Present at the H.C. Wainwright Global Life Sciences Conference in London
Apr 1, 2019 08:12AM Savara (SVRA) Commences Phase 2a Clinical Study of Molgradex for Treatment of NTM Lung Infection in People Living with CF
Apr 1, 2019 08:00AM Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection in People Living with Cystic Fibrosis
Mar 13, 2019 04:02PM Savara Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update
Mar 6, 2019 08:00AM Savara To Report Q4/Year-End 2018 Financial Results And Business Update On March 13, 2019
Mar 4, 2019 08:00AM Savara to Present at the 39th Annual Cowen and Company Healthcare Conference
Feb 6, 2019 08:06AM Savara (SVRA) Provides Update on IMPALA and AVAIL Pivotal Clinical Studies
Feb 6, 2019 08:00AM Savara Provides Update on IMPALA and AVAIL Pivotal Clinical Studies
Feb 6, 2019 08:00AM Savara Provides Update on IMPALA and AVAIL Pivotal Clinical Studies
Dec 19, 2018 08:03AM Savara (SVRA) Announces Interim Results for OPTIMA Clinical Study of Molgradex for the Treatment of NTM
Dec 19, 2018 08:00AM Savara Announces Interim Results for OPTIMA Clinical Study of Molgradex for the Treatment of NTM
Dec 19, 2018 08:00AM Savara Announces Interim Results for OPTIMA Clinical Study of Molgradex for the Treatment of NTM
View More Recent Stories View Older Stories